عربي
Posted On Jul 29, 2017

 The latest installment of the Oman Medical Journal was issued this July. Oman Med J’s Volume 32, Issue 4, July 2017 contains an editorial, review article, eight original articles, four case reports, clinical quiz, and clinical notes. In this issue, the journal approaches important issues in medical care and scientific research in medicine, and contributes new knowledge to experts and scholars as well as the public.

The editorial titled "Antibiotics Resistance: When the Armamentarium Gets to the Verge of Being Empty" talks about antibiotics which are arguably considered as one of the greatest milestones and one of the foremost lifesaving interventions in modern medicine. This is best exemplified by the impact of antibiotics on treatment of common, devastating, serious, and life threatening infections. More than 150 antibiotics have been found since the discovery of penicillin and in the last 75 years. The Editorial concludes that Living in a world without antibiotics is hard to envision. However, the truth is that the world is regrettably approaching an era in which effective antibiotics can no longer be taken for granted. When this happens, medical advances over more than half a century will, for the most part, be in jeopardy. We are obliged to avert a post antibiotic epoch and we must act now before it’s too late.

The review article titled "Using Nanoparticles in Medicine for Liver Cancer Imaging" talks about the major applications of nanoparticles in medicine for organ imaging. This article summarize some of the contrast agents used in imaging such as superparamagnetic iron oxide nanoparticles (SPIONs) and iron oxide nanoparticles (IONPs), various types of enhanced MRI for the liver, and nanoparticles like gold (AuNPs), which is used to develop novel CT imaging agents. The review concludes that there are many nanoparticles used for liver imaging. The most practical nanoparticles used in MRI and micro-CT imaging are SPION, Au, ExiTron™ Nano. The value of SPIO in the liver and spleen has been recognized by the medical research community; particularly in liver imagine where more detail is needed for the best diagnosis.

One of the original articles titled "Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience" aims to  evaluate the validity of tPSA at cut-off  ≥ 4.0 μg/L and the validity of each of tPSA, fPSA, and p2PSA in patients with different tPSA values: 0.0 μg/L to ≤  40.0 μg/L compared to prostatic biopsy for diagnosis of prostate cancer. Also, it amis to evaluate the usefulness of phi calculated from Access Hybritech p2PSA in combination with Hybritech proPSA and fPSA assays.The study concluded that Phi outperforms tPSA and fPSA when used alone or in combination, and appears to be more accurate than both markers in excluding prostate cancer before biopsy. Use of this biomarker helps clinicians to avoid unnecessary biopsies, particularly in patients with gray-zone tPSA level. Phi is the strongest marker that correlates proportionally with Gleason Score.

 

Another original article titled "Growth Pattern in Children with Systemic Lupus

Erythematosus" aims to evaluate the growth pattern in children with childhood-onset systemic lupus erythematosus (cSLE) longitudinally and identify possible risk factors. The study concluded that children with cSLE are at risk of having a negative effect on height including patients with pre-existing growth failure, high cumulative steroid dose, and longer disease duration. However, longitudinal prospective studies are needed to examine damage over time to improve health-related quality of life.  

The following case reports titles are also included in this issue:

Primary Hepatic Lymphoma Mimicking Cholangiocarcinoma, Feminizing Adrenocortical Carcinoma Without Gynecomastia, Spontaneous Coronary Artery Dissection: An Under-recognized Cause of Acute Coronary Syndromes, and First Reported Case of Arrhythmogenic Right Ventricular Cardiomyopathy in Oman.

    Oman Medical Journal was founded in 1984. It is a peer-reviewed journal, publishes six issues a year by Oman Medical Specialty Board. It intends to engage and inform doctors, researchers and other health professionals by publishing a wide range of peer-reviewed articles in various medical disciplines.  If you want to see the old issues you can visit our website http://www.omjournal.org.